Episode 17 - Enabling Immune-Oncology
This episode's guests: Dr. Roberto Salgado
This episode we are talking with Dr. Roberto Salgado, a Belgium based expert in breast pathology and immuno-oncology. He is Co-chair of the International Immuno-Oncology Biomarker Working Group.
Over the past several years, we have seen large advances and dedication of resources to immune oncology. We’ve also seen that information extracted by quantifying Tumor Infiltrating Lymphocytes on routine histologic sections adds significant predictive and prognostic information in this area.
We have known for over a hundred years, however that assessment of histologic features adds powerful information correlated with patient outcomes. Are we poised for a renaissance in histologic examination, with digital pathology as the engine?
More About Dr. Roberto Salgado
Roberto Salgado is board certified in Anatomical Pathology since 2006 and works as an Anatomic Pathologist in Antwerp, Belgium. He’s Honorary Research Associate at the Division of Research at the Peter Mac Callum Cancer Center, Melbourne, Australia, as well as being part of the Tracer-X Consortium aiming at deciphering the clonal evolutional pressures in lung and renal cancer (http://tracerx.co.uk/).
Currently, he’s co-chairing with Sherene Loi, Peter Mac Callum Cancer Center, Melbourne, Australia, and Carsten Denkert, Department of Pathology, University of Marburg, the “International Immuno-Oncology Biomarkers Working Group” (www.tilsinbreastcancer.org) that develops guidelines for the assessment of Immuno-Oncological Biomarkers in cancer.”